Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT03979612 Statut inconnu

Titre

Evaluation of the Adhesion to the Network of Care of People at Genetic Risk of Cancer in Midi-Pyrénées (GENEPY) (GENEPY)

Type

Observational [Patient Registry]

Pathologie

Syndromes néoplasiques héréditaires
Syndrome
Tumeurs de l'endomètre
Syndrome héréditaire de cancer du sein et de l'ovaire

Phase

Promoteur

Institut Claudius Regaud (Voir sur ClinicalTrials)

Date de début

août 2019

Date de fin

décembre 2020

Dernière mise à jour

29 juin 2024

Résumé

In order to best meet the needs of all those affected by the genetic risk of cancer in our region, it is important to identify the factors likely to influence the course leading to the GENEPY surveillance network. The aim of this study is to evaluatie the adhesion to the network of care of people at genetic risk of cancer in Midi-Pyrénées (GENEPY).

Détail

Voir le détail This network has been open since November 2015 for people who are genetically predisposed to breast / ovarian cancer. The extension to digestive pathologies (HNPCC syndrome, PAF) is in progress. It concerns not only the persons carrying a mutation also those belonging to a family without identified mutation but whose risk of predisposition is important. The GENEPY network is based on a collaboration between oncogenetic consultations in the region and professionals practicing in institutions (private, public) and liberal: general practitioners, gynecologists, radiologists, oncologists, gastroenterologists, psychologists ... It is therefore a multicentric and multidisciplinary network, which aims to promote the local care of people genetically predisposed (or considered at high risk of genetic predisposition), while ensuring a high level of competence, to guarantee an optimal and equitable care on the whole of Midi Pyrenees. The diagnosis of a new genetic disease in an individual is likely to have implications for other family members who may themselves be at risk of developing the disease and / or passing it on to their children. The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index) : relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients, the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring. Fermer le détail

Etablissements

Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Institut Claudius Regaud - IUCT-Oncopole - 31059 - Toulouse - Occitanie - France	Edith Chipoulet, Msc			Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

- people with an identified mutation, predisposing to tumors of the breast / ovary or
colon / rectum

- people resident in the Midi-Pyrénées region

Critère de non inclusion

- people under 18

NCT03979612 - Evaluation of the Adhesion to the Network of Care of People at Genetic Risk of Cancer in Midi-Pyrénées (GENEPY) (GENEPY)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut